Innovent Biologics, Inc.- Incyte Announce Strategic Collaboration Agreement

Delaware Bids | News

Jan 30, 2019

The agreement involves three clinical-stage product candidates discovered and developed by Incyte viz. pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor) and parsaclisi…